Immunic appoints Michael W. Bonney as Chair of Board; MS expertise ahead of trial readouts

IMMUNIC, INC.

Michael W. Bonney appointed Chair effective May 16, 2026; Simona Skerjanec transitions from Interim Chair to board member.
Bonney brings 30+ years biopharma experience, including Avonex launch at Biogen and CEO of Cubist (acquired by Merck for $9.5B).
Board size increased from 9 to 10; Bonney received option grant for 100k shares vesting over 3 years.
Company advances vidofludimus calcium toward phase 3 ENSURE readout in relapsing MS and planned PPMS program.
Simona Skerjanec remains as board member after transitioning from Interim Chair.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Simona Skerjanec

Member of the Board

IMUX · IMMUNIC, INC.

Effective: 2026-05-16
Successor: Michael W. Bonney
Filed: May 19, 2026 11:00 UTC

Simona Skerjanec, who has been serving as Interim Chairperson since February 2026, will transition from Interim Chairperson and continue to serve as a member of the Board.

Appointed

Michael W. Bonney

Chair of the Board

IMUX · IMMUNIC, INC.

Effective: 2026-05-16
Filed: May 19, 2026 11:00 UTC

appointed Michael W. Bonney as Chair of the Board, effective immediately.

Source: SEC EDGAR

accession 0001193805-26-000645

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.